CASE SUBMISSION GUIDELINES
The workshop panel will collate and discuss all cases submitted to the Workshop. All cases will be organized into eight sessions using the topics chosen by the submitter in the online system but may be rescheduled at the discretion of the Workshop Panel. Approximately 40 cases (4 or 5 cases per session) will be presented during the meeting. Early submissions are strongly encouraged.
Alert! Case Submission will open in Fall 2026
Case Topics
- The focus of the 2027 Workshop is hematolymphoid disorders arising in the setting of immune dysregulation.
- Lymph node, extranodal, and bone marrow pathology in primary immune deficiency (PID)
- Examples of various PIDs such as (but not limited to) chronic variable immunodeficiency (CVID), hyper IgM syndrome, PI3K-related immunodeficiencies, Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) deficiency, autoimmune lymphoproliferative syndrome (ALPS), WHIM syndrome, etc.
- Post-transplant lymphoproliferative disorder (PTLD; excluding monomorphic PTLD unless listed below)
- Non-destructive PTLD – i.e. infectious mononucleosis-like, follicular hyperplasia and plasmacytic hyperplasia
- PTLD cases which highlight the difficulties in differentiating between polymorphic and monomorphic PTLD
- T- and NK-cell PTLDs
- Iatrogenic immunodeficiency-associated hematolymphoid disorders
- Examples of myeloid and lymphoid proliferations and neoplasms in patients on various immunosuppressive/ immunomodulatory agents, including newer agents (such as monoclonal antibodies, gene therapy, and CAR T-cell therapy), for example CAR T-derived lymphoproliferative disorders
- Lenalidomide-associated myeloid and/or lymphoid neoplasms
- Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPD)
- Cases with overlapping features between EBV-positive classic Hodgkin lymphoma, EBV positive NLP, and EBV-positive diffuse large B-cell lymphoma
- Lymphomatoid granulomatosis
- EBV-positive polymorphic B-cell LPD, NOS
- EBV-positive plasma cell neoplasms (excluding plasmablastic lymphoma) – i.e. EBV-positive plasmacytoma and plasma cell myeloma
- EBV-positive nodal PTCL
- Somatic mutations associated with immune dysregulation and neoplasia
- VEXAS
- RAS-associated autoimmune leukoproliferative disorder (RALD)
- Examples of cases with somatic mutations associated with hemophagocytic lymphohistiocytosis (HLH), such as FAS mutations
- Examples of lymphoid neoplasms arising in setting of clonal hematopoiesis of indeterminate potential (CHIP), excluding T-follicular helper lymphomas
- Bone marrow pathology associated with immune dysregulation
- Myeloid neoplasia and mimics arising in the setting of immune-acting drugs other than alkylating or topoisomerase-inhibitor chemotherapy, such as azathioprine, antithymocyte globulin, methotrexate
- Autoimmune myelofibrosis and other bone marrow changes associated with autoimmunity
- HIV-associated myeloid disorders and alterations to the bone marrow microenvironment